
CLAIMS

WHAT IS CLAIMED IS:

1. A compound of Formula I




Formula I

or a pharmaceutical acceptable salt thereof wherein:

A1 is phenyl or a 6-membered heteroaromatic ring having 1, 2 or 3 N in the heteroaromatic ring;

A2 is ~~selected from~~ A2a ~~or A2b~~



A2a

~~or~~ 

~~A2b~~

wherein A2a is phenyl or a 6 membered heteroaromatic ring having 1, 2 or 3 N in the heteroaromatic ring, and

~~A2b is a 5 membered heteroaromatic ring having 1, 2 or 3 heteroatoms independently selected from O, S and N;~~

X is selected from the group consisting of $-(CH_2)_2-$, $-(CH_2)_3-$, $-(CH_2)_4-$, and $-(CH_2)_m-O-(CH_2)_n-$, optionally mono- or di-substituted with halogen, wherein m and n are independently 0, 1, 2, 3 or 4, with the proviso that m+n is 2, 3 or 4;

Y is O;

R^1 and R^2 are each independently selected from the group consisting of:

(a) hydrogen,
(b) halogen,
(c) CN,
(d) CF_3,
(e) $-C_{1-6}$alkyl,
(f) $-C_{1-6}$alkyl-C(=O)OH,
(g) $-O-(R^7)$,
(h) $-S(=O)_oR^7$,

(ff) -C_{3-6}cycloalkyl-S(=O)$_2$N(R^7)(R^8),
(gg) -C_{3-6}cycloalkyl-N(R^7)C(=O)O(R^8),
(hh) -C_{3-6}cycloalkyl-O-C(=O)N(R^7)(R^8),
(ii) -C_{3-6}cycloalkyl-C(=O)(R^7),
(jj) -C_{3-6}cycloalkyl-C(R^7)(R^8)OH,
(kk) -C_{3-6}cycloalkyl-O(R^7),
(ll) -C(=O)OH,
(mm) aryl,
(nn) heteroaryl,
(oo) -C(=O)N(R^7)S(=O)$_2$(R^8),
(pp) -S(=O)$_2$N(R^7)C(=O)(R^8),
(qq) -NHS(=O)$_2$N(R^7)(R^8),
(rr) -NHC(=O)N(R^7)(R^8),
(ss) -CH(OH)–C(=O)–N(R^7)(R^8),
(tt) -C(=O)–C(=O)–N(R^7)(R^8),
(uu) -C_{3-6}cycloalkyl,
(vv) -CF_3,
(ww) -C_{1-6}alkyl N(R^7)(R^8),
(xx) -heterocycle,
(yy) -C_{1-6}alkyl,
(zz) halogen, and
(aaa) -O-C_{1-6}alkyl-N(R^7)(R^8),

wherein the alkyl portion of choices (m), (n), (o), (p), (q), (r), (s), (t), (u), (v), (w), (x), (ww), (yy) and (aaa), the alkenyl portion of choice (y), and the cycloalkyl portion of choices (z), (aa), (bb), (cc), (dd), (ee), (ff), (gg), (hh), (ii), (jj), (kk) and (uu), are optionally mono- or di-substituted with halogen, CN, aryl, C_{1-6}alkyl, halo C_{1-6}alkyl, C_{3-6}cycloalkyl, C_{1-6}alkoxy, or C_{3-6} cycloalkoxy, and

wherein the aryl of choice (mm), the heteroaryl of choice (nn), and the heterocycle of choice (xx) are optionally mono- or di-substituted with substituents selected from halogen, nitro, C_{1-6}alkyl, C_{1-6}alkoxy, halo C_{1-6}alkyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkoxy, -NH(C_{1-6}alkyl), -NH(C_{3-6} cycloalkyl), -N(C_{1-6}alkyl)$_2$, -N(C_{3-6}cycloalkyl)$_2$, -S(=O)$_o$$C_{1-6}$alkyl, -S(=O)$_o$$C_{3-6}$cycloalkyl, hydroxyl and CN, or

wherein R^3 and R^4 or R^4 and $R^{4'}$ are joined together to form a 5- or 6-membered heterocyclic ring, said ring having one heteroatom selected from O and N, wherein said ring is optionally substituted with -C(=O)OH, or -C_{1-6}alkyl-C(=O)OH, with the proviso that at least one of R^3, R^4 and $R^{4'}$ is other than hydrogen;

R^5 is -C_{1-6}alkyl optionally substituted with halogen or C_{1-4}alkyl; ~~selected from the group consisting of:~~

~~(a) hydrogen,~~

~~(b) -C_{1-6}alkyl,~~

~~(c) -C_{1-4}alkyl(R^7),~~

~~(d) aryl,~~

~~(e) heteroaryl,~~

~~(f) -C_{3-6}cycloalkyl,~~

~~(g) -C_{3-6}cycloalkyl(R^7),~~

~~(h) -C_{3-6}cycloalkyl-O(R^7),~~

~~(i) -C_{1-4}alkyl-C_{3-6}cycloalkyl,~~

~~(j) C_{1-6}alkoxy, and~~

~~(k) C_{3-6}cycloalkoxy,~~

~~wherein the alkyl portion of choices (b), (c), (i) and (j), the cycloalkyl portion of choices (f), (g), (h), (i) and (k) are optionally substituted with halogen or C_{1-4}alkyl, and~~

~~wherein the aryl of choice (d) and the heteroaryl of choice (e), are optionally mono- or di-substituted with substituents selected from halogen, nitro, C_{1-6}alkyl, CF_3, C_{1-6}alkoxy, halo C_{1-6} alkyl, aryl, heteroaryl, C_{3-6}cycloalkyl, C_{3-6}cycloalkoxy, and CN;~~

R^6 is selected from the group consisting of~~:~~ -C_{1-6}alkylaryl and -C_{1-6}alkylheteroaryl, wherein the alkyl portion of the -C_{1-6}alkylaryl and the -C_{1-6}alkylheteroaryl are optionally substituted with halogen or C_{1-4}alkyl, and the aryl and heteroaryl portions of the C_{1-6}alkylaryl and the -C_{1-6}alkylheteroaryl are optionally mono- or di-substituted with substituents selected from halogen, nitro, -CF_3, C_{1-6}alkyl, C_{1-6}alkoxy, halo C_{1-6}alkyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkoxy, aryl, heteroaryl, heterocycle optionally substituted with halogen, -NH(C_{1-6}alkyl), -NH(C_{3-6}cycloalkyl), -N(C_{1-6} alkyl)$_2$, -N(C_{3-6}cycloalkyl)$_2$, -S(=O)$_o$$C_{1-6}$alkyl, S(=O)$_o$$C_{3-6}$cycloalkyl, and CN;

~~(a) hydrogen,~~

~~(b) -C_{1-6}alkyl,~~

~~(c) -C_{1-6}alkylaryl,~~

~~(d) -C_{1-6}alkylheteroaryl,~~

~~(e) -S(=O)$_o$$C_{1-6}$alkyl($R^7$),~~

~~(f) -C(=O)C_{1-6}alkyl(R^7),~~

~~(g) -C_{3-6}cycloalkyl,~~

~~(h) aryl,~~

~~(i) hetereoaryl,~~

~~(j) -C(=O)C_{3-6}cycloalkyl(R^7),~~

~~(k) -S(=O)$_o$$C_{3-6}$cycloalkyl($R^7$), and~~

~~(l) -C_{1-6}alkyl(R^7),~~

~~wherein the alkyl portion of choices (b), (c), (d), (e), (f), and (l) and the cycloalkyl portion of choices (g), (j), and (k), are optionally substituted with halogen or C_{1-4}alkyl, and~~

~~wherein the aryl portion of choices (c) and (h), and the heteroaryl portion of choices (d) and (i), are optionally mono- or di-substituted with substituents selected from halogen, nitro, $-CF_3$, C_{1-6}alkyl, C_{1-6}alkoxy, halo C_{1-6}alkyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkoxy, aryl, heteroaryl, heterocycle optionally substituted with halogen, $-NH(C_{1-6}$alkyl), $-NH(C_{3-6}$cycloalkyl), $-N(C_{1-6}$alkyl)$_2$, $-N(C_{3-6}$cycloalkyl)$_2$, $S(=O)_oC_{1-6}$alkyl, $S(=O)_oC_{3-6}$cycloalkyl, and CN;~~

R^7 and R^8 are each independently selected from the following:

(a) hydrogen,
(b) -C_{1-6}alkyl,
(c) -C_{3-6}cycloalkyl,
(d) -aryl,
(e) -heteroaryl,
(f) -C_{1-6}alkylaryl,
(g) -C_{1-6}alkylheteroaryl,
(h) -C(=O)C_{1-6}alkyl,
(i) -$S(=O)_o$-aryl,
(j) -C_{1-6}alkyl-C_{3-6}cycloalkyl, and
(k) CF_3,

wherein the alkyl of choices (b), (f), (g), (h), and (j), and the cycloalkyl of choices (c) and (j), are each optionally mono-, di- or tri-substituted with halogen, and

wherein the aryl portion of choices (d), (f) and (i), and the heteroaryl portion of choices (e) and (g), are each optionally mono- or di-substituted with substituents selected from halogen, -C(=O)OH, $-CF_3$, $-NHC(=O)CH_3$, nitro, C_{1-6}alkyl, C_{1-6}alkoxy, halo C_{1-6}alkyl, C_{3-6}cycloalkyl, C_{3-6} cycloalkoxy, $-NH(C_{1-3}$alkyl), $-NH(C_{3-6}$cycloalkyl), $-N(C_{1-3}$alkyl)$_2$, $-N(C_{3-6}$cycloalkyl)$_2$, $-S(=O)_oC_{1-4}$alkyl, $S(=O)_oC_{3-6}$cycloalkyl, aryl, heteroaryl, hydroxyl, and CN;

R^9 and R^{10} are each independently selected from the following:

(a) hydrogen,

(b) -C_{1-6}alkyl,

~~(c) -C_{3-6}cycloalkyl,~~

(~~d~~c) halogen,

~~(e) -OC_{3-6}cycloalkyl,~~

(~~f~~d) CF_3, and

(~~g~~e) C_{1-6}alkoxy,

wherein the alkyl portion of choice (b) is ~~and the cycloalkyl portion of choices (c) and (e), are each~~ optionally mono-, di- or tri- substituted with halogen; and

wherein each o is independently 0, 1, or 2.

2. A compound according Claim 1, or a pharmaceutically acceptable salt thereof, wherein:

X is selected from -$CH_2CH_2CH_2$-, or -$CF_2CH_2CH_2$-.

3. A compound according Claim 1, or a pharmaceutically acceptable salt thereof, wherein: A2 is ~~A2a and A2a is~~ a substituted phenyl, substituted pyrimidine, substituted pyrazine, or substituted pyridine.

4. A compound according Claim 1, or a pharmaceutically acceptable salt thereof, wherein:

R^1 and R^2 are each independently selected from the group consisting of:

(a) hydrogen,
(b) halogen,
(c) CN,
(d) CF_3,
(e) -$C_{1\text{-}6}$alkyl,
(f) -O-(R^7),
(g) -$C_{3\text{-}6}$cycloalkyl, and
(h) -N(R^7)(R^8),

wherein the alkyl portion of choice (e) and the cycloalkyl portion of choice (g) are optionally substituted with halogen.

5. A compound according Claim 1, or a pharmaceutically acceptable salt thereof, wherein:

R^1 and R^2 are each hydrogen.

6. A compound according Claim 1, or a pharmaceutically acceptable salt thereof, wherein:

R^3 is selected from the group consisting of:

(a) hydrogen,
(b) -O-(R^7),
(c) -N(R^7)S(=O)$_2$(R^8), and
(d) -$C_{1\text{-}6}$alkyl,

wherein the alkyl portion of choice (d) is optionally substituted with halogen or hydroxyl.

7. A compound according Claim 1, or a pharmaceutically acceptable salt thereof, wherein:

R^4 and $R^{4'}$ are each independently selected from the group consisting of:

(a) hydrogen,

8. A compound according to Claim 1, or a pharmaceutically acceptable salt thereof wherein:

R^4 and $R^{4'}$ are each independently selected from the group consisting of:

(a) $-C(R^7)(R^8)OH$,
(b) $-N(R^7)S(=O)_2R^8$,
(c) $-O-(R^7)$,
(d) $-C_{1-6}$alkyl-C(=O)OH,
(e) -C(=O)OH,
(f) $-NHS(=O)_2N(R^7)(R^8)$,
(g) $-C_{3-6}$cycloalkyl,
(h) CF_3,
(i) heterocycle,
(j) $-C_{1-6}$alkyl, and
(k) halogen,

wherein the alkyl portion of choices (d) and (j), and the cycloalkyl portion of choice (g) are optionally mono- or di-substituted with halogen, CN, aryl, C_{1-6}alkyl, halo C_{1-6}alkyl, C_{3-6} cycloalkyl, C_{1-6}alkoxy, or C_{3-6}cycloalkoxy, and

wherein the heterocycle of choice (i) is optionally mono- or di-substituted with substituents selected from halogen, hydroxyl, nitro, C_{1-6}alkyl, C_{1-6}alkoxy, halo C_{1-6}alkyl, C_{3-6} cycloalkyl, C_{3-6}cycloalkoxy, $-NH(C_{1-6}alkyl)$, $-NH(C_{3-6}cycloalkyl)$, $-N(C_{1-6}alkyl)_2$, $-N(C_{3-6}$ $cycloalkyl)_2$, $-S(=O)_oC_{1-6}$alkyl, $-S(=O)_oC_{3-6}$cycloalkyl, and CN.

9. A compound according Claim 1, or a pharmaceutically acceptable salt thereof, wherein: R^6 is $-C_{1-6}$alkylheteroaryl, wherein the alkyl portion of the $-C_{1-6}$alkylheteroaryl is optionally substituted with halogen or C_{1-4}alkyl, and the heteroaryl portion of the $-C_{1-6}$alkylheteroaryl is optionally mono- or di-substituted with substituents selected from halogen, nitro, CF_3, C_{1-6}alkyl, C_{1-6}alkoxy, halo C_{1-6}alkyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkoxy, aryl, heteroaryl, heterocycle optionally substituted with halogen, $-NH(C_{1-6}alkyl)$, $-NH(C_{3-6}cycloalkyl)$, $-N(C_{1-6}$ $alkyl)_2$, $-N(C_{3-6}cycloalkyl)_2$, $-S(=O)_oC_{1-6}$alkyl, $-S(=O)_oC_{3-6}$cycloalkyl, and CN.~~A compound according Claim 1, or a pharmaceutically acceptable salt thereof, wherein: R^5 is selected from the group consisting of:~~

~~(a) hydrogen,~~
~~(b) $-C_{1-6}$alkyl, and~~
~~(c) $-C_{1-4}alkyl(R^7)$,~~

~~wherein the alkyl portion of choices (b) and (c) are optionally substituted with halogen or C_{1-4}alkyl. .~~

10. A compound according Claim 1, or a pharmaceutically acceptable salt thereof, wherein: R^6 is -C_{1-6}alkylaryl, wherein the alkyl portion of the -C_{1-6}alkylaryl is optionally substituted with halogen or C_{1-4}alkyl, and the aryl portion of the -C_{1-6}alkylaryl is optionally mono- or di-substituted with substituents selected from halogen, nitro, CF_3, C_{1-6}alkyl, C_{1-6}alkoxy, halo C_{1-6}alkyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkoxy, aryl, heteroaryl, heterocycle optionally substituted with halogen, -NH(C_{1-6}alkyl), -NH(C_{3-6}cycloalkyl), -N(C_{1-6} alkyl)$_2$, -N(C_{3-6}cycloalkyl)$_2$, -S(=O)$_o$$C_{1-6}$alkyl, -S(=O)$_o$$C_{3-6}$cycloalkyl, and CN.~~selected from the group consisting of: (a) -C_{1-6}alkylaryl,~~

~~(b) -C_{1-6}alkylheteroaryl,~~

~~(c) -C_{1-6}alkyl(R^7),~~

~~wherein the alkyl portion of choices (a), (b) and (c), are optionally substituted with halogen or C_{1-4}alkyl, and~~

~~wherein the aryl portion of choice (a)is optionally mono- or di-substituted with substituents selected from halogen, nitro, CF_3, C_{1-6}alkyl, C_{1-6}alkoxy, halo C_{1-6}alkyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkoxy, aryl, heteroaryl, heterocycle optionally substituted with halogen, -NH(C_{1-6}alkyl), -NH(C_{3-6}cycloalkyl), -N(C_{1-6} alkyl)$_2$, -N(C_{3-6}cycloalkyl)$_2$, -S(=O)$_o$$C_{1-6}$alkyl, -S(=O)$_o$$C_{3-6}$cycloalkyl, and CN.~~

~~11. A compound according Claim 1, or a pharmaceutically acceptable salt thereof, wherein: R^9 and R^{10} are each independently~~

~~(a) hydrogen,~~

~~(b) -C_{1-6}alkyl,~~

~~(c) halogen,~~

~~(d) CF_3, and~~

~~(e) C_{1-6}alkoxy,~~

~~wherein the alkyl of choice (b) is optionally mono-, di- or tri-substituted with halogen.~~

~~12~~11. A compound according to Claim 1~~1~~, or a pharmaceutically acceptable salt thereof, wherein:

A2 is ~~A2a, and A2a is~~ a substituted phenyl, substituted pyrimidine, substituted pyrazine, or substituted pyridine;

R^1 and R^2 are each independently selected from:

(a) hydrogen,

(b) halogen,

(c) CF_3,

(d) $C_{1\text{-}6}$alkyl, and

(e) -O-(R^7),

wherein the alkyl portion of choice (d) is optionally substituted with halogen;

R^3 is selected from the group consisting of:

(a) hydrogen,

(b) -O-(R^7),

(c) -N(R^7)S(=O)$_2$(R^8), and

(d) -$C_{1\text{-}6}$alkyl,

wherein the alkyl portion of choice (d) is optionally substituted with halogen or hydroxyl;

R^4 and $R^{4'}$ are each independently selected from the group consisting of:

(a) -C(R^7)(R^8)OH,

(b) -N(R^7)S(=O)$_2R^8$,

(c) -O-(R^7),

(d) -$C_{1\text{-}6}$alkyl-C(=O)OH,

(e) -C(=O)OH,

(f) -NHS(=O)$_2$N(R^7)(R^8),

(g) $C_{3\text{-}6}$cycloalkyl,

(h) CF_3,

(i) heterocycle,

(j) -$C_{1\text{-}6}$alkyl, and

(k) halogen,

wherein the alkyl portion of choices (d) and (j), and the cycloalkyl portion of choice (g) are optionally mono- or di-substituted with halo, CN, aryl, $C_{1\text{-}6}$alkyl, halo $C_{1\text{-}6}$alkyl, $C_{3\text{-}6}$ cycloalkyl, $C_{1\text{-}6}$alkoxy, or $C_{3\text{-}6}$cycloalkoxy, and

wherein the heterocycle of choice (i) is optionally mono- or di-substituted with substituents selected from halogen, hydroxyl, nitro, $C_{1\text{-}6}$alkyl, $C_{1\text{-}6}$alkoxy, halo $C_{1\text{-}6}$alkyl, $C_{3\text{-}6}$ cycloalkyl, $C_{3\text{-}6}$cycloalkoxy, -NH($C_{1\text{-}6}$alkyl), -NH($C_{3\text{-}6}$cycloalkyl), -N($C_{1\text{-}6}$alkyl)$_2$, -N($C_{3\text{-}6}$ cycloalkyl)$_2$, -S(=O)$_o$$C_{1\text{-}6}$alkyl, -S(=O)$_o$$C_{3\text{-}6}$cycloalkyl, and CN;

R^5 is -$C_{1\text{-}6}$alkyl, optionally substituted with halogen or $C_{1\text{-}4}$alkyl; ~~selected from the group consisting of:~~

~~(a) hydrogen,~~

~~(b) -$C_{1\text{-}6}$alkyl, and~~

~~(c) -$C_{1\text{-}4}$alkyl(R^7),~~

~~wherein the alkyl portion of choices (b) and (c) is optionally substituted with halogen or $C_{1\text{-}4}$alkyl;~~

R^6 is -C_{1-6}alkylaryl or -C_{1-6}alkylheteroaryl, and ~~selected from the group consisting of:~~

~~(a) -C_{1-6}alkylaryl,~~


~~(b) -C_{1-6}alkylheteroaryl, and~~

~~(c) -C_{1-6}alkyl(R^7),~~

wherein the alkyl portion of the C_{1-6}alkylaryl and the -C_{1-6}alkylheteroaryl ~~choices (a), (b), and (c) is~~are optionally substituted with halogen or C_{1-4}alkyl, and

wherein the aryl portion the C_{1-6}alkylaryl ~~of choice (a),~~ and the heteroaryl portion of the -C_{1-6}alkylheteroaryl~~choice (b)~~, are optionally mono- or di-substituted with substituents selected from halogen, nitro, CF_3, C_{1-6}alkyl, C_{1-6}alkoxy, halo C_{1-6}alkyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkoxy, aryl, heteroaryl, heterocycle optionally substituted with halogen, -NH(C_{1-6}alkyl), -NH(C_{3-6}cycloalkyl), -N(C_{1-6}alkyl)$_2$, -N(C_{3-6} cycloalkyl)$_2$, -S(=O)$_o$$C_{1-6}$alkyl, -S(=O)$_o$$C_{3-6}$cycloalkyl, and CN.


~~13~~12. A compound according to Claim ~~12~~ 11 of Formula 1a



1a

or a pharmaceutically acceptable salt thereof.

~~14~~13. A compound according to Claim ~~13~~ 12 of Formula 1b



1b

or a pharmaceutically acceptable salt thereof.

~~15~~14. A compound according to Claim 1 selected from the group consisting of:

2-(3'-(3-(1-(4-(*tert*-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)propyl)-[1,1'-biphenyl]-3-yl)acetic acid,

2-(3'-(3-(1-(4-(*tert*-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)propyl)-[1,1'-biphenyl]-4-yl)acetic acid,

3'-(3-(1-(4-(*tert*-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)propyl)-[1,1'-biphenyl]-3-carboxylic acid,

2-(5-(6-(3-(1-(4-(*tert*-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)propyl)pyrimidin-4-yl)-2-ethoxyphenyl)acetic acid,

(3'-(3-(1-(4-(tert-Butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-3-methoxy-[1,1'-biphenyl]-4-yl)acetic acid,

(3'-(3-(1-(4-(tert-Butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-3-ethoxy-[1,1'-biphenyl]-4-yl)acetic acid,

(3'-(3-(1-(4-(tert-Butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-3-propoxy-[1,1'-biphenyl]-4-yl)acetic acid,

2-(3'-(3-(1-(4-(*tert*-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)propyl)-3-hydroxy-[1,1'-biphenyl]-4-yl)acetic acid,

2-(3'-(3-(1-(4-(*tert*-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)propyl)-4-isopropoxy-[1,1'-biphenyl]-3-yl)acetic acid, and

2-(3'-(3-(1-(4-(*tert*-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)propyl)-4-(2-(dimethylamino)ethoxy)-[1,1'-biphenyl]-3-yl)acetic acid,

or a pharmaceutically acceptable salt thereof.

~~16~~15. A compound according to Claim 1 selected from the group consisting of:

3'-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1'-biphenyl]-4-carboxylic acid;

2-(3'-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-ethoxy-[1,1'-biphenyl]-3-yl)acetic acid;

1-(3'-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1'-biphenyl]-3-yl)cyclopropanecarboxylic acid;

2-(3'-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-propoxy-[1,1'-biphenyl]-3-yl)acetic acid;

2-(3'-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-fluoro-[1,1'-biphenyl]-3-yl)acetic acid;

2-(3'-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)-1,1-difluoropropyl)-4-ethoxy-[1,1'-biphenyl]-3-yl)acetic acid;

(3'-(3-(1-(4-(tert-Butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-3-ethoxy-[1,1'-biphenyl]-4-yl)acetic acid;

(3'-(3-(1-(4-(tert-Butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-3-propoxy-[1,1'-biphenyl]-4-yl)acetic acid,

or a pharmaceutically acceptable salt thereof.

~~17~~16. A pharmaceutical composition comprising a compound according to Claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

~~18~~17. A compound according to Claim 1 for use in treating a cancer in a mammal which is negatively impacted by diminution in its metabolism of fatty acid, through the adminstration of a therapeutically effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt thereof, to the mammal in need thereof, wherein said cancer is selected from prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia and melanoma.